Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma (NeoPancOne)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04472910
Recruitment Status : Recruiting
First Posted : July 16, 2020
Last Update Posted : May 12, 2021
Sponsor:
Collaborator:
Pancreatic Cancer Canada
Information provided by (Responsible Party):
University Health Network, Toronto

Tracking Information
First Submitted Date  ICMJE June 23, 2020
First Posted Date  ICMJE July 16, 2020
Last Update Posted Date May 12, 2021
Actual Study Start Date  ICMJE August 21, 2020
Estimated Primary Completion Date December 31, 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 14, 2020)
To assess disease free survival (DFS) in resectable PDAC treated with peri-operative mFFX according to baseline GATA6 expression level [ Time Frame: 2-4 years ]
Disease free survival
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 14, 2020)
  • Evaluate the feasibility of EUS FNB as an effective modality for the detection of GATA6 expression at first diagnosis, including number of unsuccessful EUS-FNBs. [ Time Frame: 2-4 years ]
  • Determine GATA6 in-situ hybridization (ISH)/immunohistochemistry (IHC) success rate [ Time Frame: 2-4 years ]
  • Determine GATA6 expression levels in EUS-FNB specimen compared to surgical specimen [ Time Frame: 2-4 years ]
  • Determine the DFS according to R0 or R1 resection status [ Time Frame: 2-4 years ]
  • Determine the DFS according to baseline Ca19.9 levels [ Time Frame: 2-4 years ]
  • Determine the DFS according to modified Moffitt RNA classification [ Time Frame: 2-4 years ]
  • To determine the overall response rate (ORR) to neoadjuvant mFFX [ Time Frame: 2-4 years ]
  • Determine the percentage of patients who progress on neoadjuvant mFFX [ Time Frame: 2-4 years ]
  • Assess pathological response rate to mFFX in the neoadjuvant setting [ Time Frame: 2-4 years ]
  • Determine the overall survival (OS) according to GATA6 expression level in the overall population and the GATA6 high/low populations [ Time Frame: 2-4 years ]
  • Determine the overall survival (OS) according to R0/R1 resection status in the overall population and the GATA6 high/low populations [ Time Frame: 2-4 years ]
  • Determine the overall survival (OS) according to baseline Ca19.9 levels in the overall population and the GATA6 high/low populations [ Time Frame: 2-4 years ]
  • Determine the overall survival (OS) according modified Moffitt classification in the overall population and the GATA6 high/low populations [ Time Frame: 2-4 years ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
Official Title  ICMJE GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma: A Multicentre Canadian Phase II Study
Brief Summary To date, there have been no Canadian led neoadjuvant or peri-operative trials, this multicentre design gives the opportunity to build more experience with this strategy across Canada in more institutions. The design of this prospective trial will also test our important hypotheses regarding the use of biomarkers to understand the benefit of mFFX in improving outcomes for patients with resectable pancreas cancer. Data from this study would likely inform future studies where patients are given personalised options for the best treatment strategies rather than one empiric approach.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Resectable Pancreatic Cancer
Intervention  ICMJE Drug: Modified Folforinox (mFFX)
Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
Other Name: Folfirinox or other approach
Study Arms  ICMJE Experimental: Neo-adjuvant mFFX
Neo-adjuvant mFFX up to 6 cycles, surgery, adjuvant chemotherapy for up tp 6 cycles, follow up
Intervention: Drug: Modified Folforinox (mFFX)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 14, 2020)
84
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2025
Estimated Primary Completion Date December 31, 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with a histological diagnosis of PDAC. Those with unconfirmed histology must have this confirmed by EUS-FNB in the pre-screening period prior to commencement of chemotherapy. Invasive PDAC in the setting of intraductal papillary mucinous neoplasm (IPMN) is permitted.
  • Patients must consent to EUS-FNB for correlative analysis even if adenocarcinoma has been confirmed, unless confirmation was performed using a previous biopsy or fine needle biopsy with adequate tumour tissue for GATA6 analysis.
  • Resectable primary tumour on preoperative biphasic (arterial and venous phases) contrast-enhanced CT for pancreatic staging as per institutional standard of care, with ≤5 mm slice thickness. MRI for liver metastases (optional) as per institutional standard of care. The definition of resectability (as per NCCN guidelines - see Appendix B) includes:

    • no involvement of the celiac artery, common hepatic artery or superior mesenteric artery (or if present a replaced right or common hepatic artery)
    • no involvement or <180 (interface between tumour and vessel wall, of the portal vein or superior mesenteric vein, and patent portal vein/splenic vein confluence_
    • For tumours of the body and tail of the pancreas, involvement of the splenic artery and vein of any degree is considered resectable disease
  • Patients must be medically fit to undergo surgical resection
  • No prior oncological treatment for index PDAC
  • ECOG Performance status 0-1
  • Age > 18 years
  • Patients must be medically suitable for treatment with mFFX as per treating medical oncologist
  • No evidence of metastases (i.e., metastatic work-up negative including a CT scan of the chest, abdomen (IV and oral contrast, 3 phase) and pelvis)
  • Adequate hematologic function

    • absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
    • platelets ≥ 100 000 cells/mm3
    • hemoglobin ≥ 9 g/L (after transfusion is acceptable))
  • Creatinine level < 130 µmol/L or CrCl ≥ 50 ml/min
  • Patients of child-bearing potential (for female patient: study entry after a menstrual period and a negative pregnancy test) must agree to use two medically acceptable methods of contraception (one for the patient and one for their partner) during the study and for 4 months after the last study treatment intake for women and 6 months for men. These patients must have a pregnancy test repeated every month while on chemotherapy.
  • Patients must be able to provide written informed consent
  • Adequate liver function (AST <2.5 times the institutional upper limit of normal at the baseline visit, total bilirubin ≤ 2 times the institutional upper limit of normal at the baseline visit)

Exclusion Criteria:

  • Patients where attempted EUS-FNB x 2 has not confirmed PDAC in the setting of unconfirmed histology.
  • Patients in whom histology has confirmed PDAC but who do not consent to EUS-FNB, unless previous confirmation was by biopsy or fine needle biopsy with adequate tumour tissue for GATA6 analysis.
  • Non-ductal pancreas tumours including endocrine tumours, acinar cell carcinoma, cyst adenocarcinoma or ampullary tumours.
  • Unresectable PDAC by contrast enhanced CT or MRI. Borderline resectable PDAC (vein and artery) are excluded from this study
  • Evidence of metastatic disease
  • Prior treatment for index PDAC
  • Previous autologous bone marrow transplant or stem cell rescue
  • Active hepatitis B or C infection
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
  • History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early stage prostate cancer or curatively treated cervical carcinoma in situ or other indolent malignancy (discretion of PI).
  • Pregnant or breast-feeding patients are excluded from this study as the chemotherapy agents used in this study have been demonstrated or have the potential to be teratogenic and there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother
  • Patients who are being therapeutically anticoagulated with coumadin and cannot have an alternative anticoagulation regimen.
  • Known hypersensitivity to any of the drugs used or their components.
  • Patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity.
  • History of QT prolongation or receiving QT prolonging medications.
  • History of Gilberts condition
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Anna Dodd 647-539-6498 anna.dodd@uhn.ca
Contact: Roxana Bucur 437-772-4354 roxana.bucur@uhn.ca
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04472910
Other Study ID Numbers  ICMJE 19-6059
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party University Health Network, Toronto
Study Sponsor  ICMJE University Health Network, Toronto
Collaborators  ICMJE Pancreatic Cancer Canada
Investigators  ICMJE
Principal Investigator: Jennifer Knox, MD Princess Margaret Cancer Centre, University Health Network
PRS Account University Health Network, Toronto
Verification Date May 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP